BETHESDA, Md., July 2, 2026
Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will deliver a scientific presentation at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS) highlighting new analyses evaluating the association between DCVax®-L treatment and patient survival. The presentation, titled “DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses,” is scheduled for July 3, 2026, at 10:00 a.m. GMT and will examine survival outcomes using propensity score matching (PSM), a widely accepted statistical methodology designed to reduce bias when comparing treatment groups. The company also confirmed that the presentation slide deck will be made publicly available on its corporate website following the scientific session, enabling researchers, clinicians, and investors to review the findings presented at one of the leading neuro-oncology conferences.
Propensity Score Matching Provides Additional Evaluation of Clinical Benefit
The upcoming presentation focuses on applying propensity score matching, an advanced statistical technique frequently used in clinical research to compare patient populations with similar baseline characteristics when randomized comparisons are limited. Northwest Biotherapeutics intends to demonstrate how this analytical approach further evaluates the relationship between DCVax-L therapy and overall survival in patients with glioblastoma (GBM). By carefully matching treated patients with comparable control populations, the methodology aims to minimize potential confounding variables and strengthen interpretation of survival outcomes. The company believes these analyses add another layer of scientific evidence supporting the clinical activity of its personalized dendritic cell vaccine while contributing valuable insights to the ongoing discussion surrounding innovative treatment strategies for one of the most aggressive forms of brain cancer.
DCVax-L Remains the Company’s Lead Personalized Cancer Immunotherapy
DCVax-L is Northwest Biotherapeutics’ lead investigational personalized dendritic cell-based immunotherapy, designed to stimulate a patient’s immune system to recognize and attack tumor cells. The therapy is being developed primarily for the treatment of glioblastoma, an aggressive and rapidly progressing primary brain cancer with limited therapeutic options and poor long-term survival rates. Northwest Biotherapeutics has completed a 331-patient Phase 3 clinical trial evaluating DCVax-L in GBM, with study findings previously presented at international scientific meetings and published in JAMA Oncology. The company has also submitted a Marketing Authorization Application (MAA) for commercial approval in the United Kingdom, where the application remains under regulatory review. Beyond glioblastoma, Northwest continues to expand its immunotherapy platform through additional programs including DCVax-Direct for inoperable solid tumors and earlier-stage research in ovarian cancer.
Advertisement
Scientific Engagement Supports Continued Development of DCVax Platform
Participation in the British Neuro-Oncology Society Annual Meeting underscores Northwest Biotherapeutics’ ongoing commitment to expanding the scientific understanding of personalized cancer immunotherapy through rigorous clinical research and advanced statistical evaluation. By presenting updated analyses using propensity score matching, the company aims to provide clinicians, researchers, and regulatory stakeholders with additional evidence regarding the potential long-term survival benefits associated with DCVax-L treatment. As regulatory review of the therapy continues in the United Kingdom and future clinical development progresses, Northwest Biotherapeutics remains focused on advancing its dendritic cell vaccine platform for patients with glioblastoma and other difficult-to-treat solid tumors. The presentation also reflects the growing importance of robust analytical methodologies in validating clinical outcomes and supporting future oncology treatment strategies.
Source: Northwest Biotherapeutics, press release
